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02 The Journal of Thoracic and Cardiobjective: Numerous reports have been published documenting the results of aortic
alve replacement. It is often not easy to translate these outcomes involving the
ondition of the valve into the actual consequences for the patient. We previously
eveloped an alternative method to study outcome after aortic valve replacement
hat allows direct estimation of patient outcome after aortic valve replacement:
icrosimulation modeling. The goal of this article is to provide insight into
icrosimulation methodology and to give an overview of the advantages and
isadvantages of simulation methods (in particular microsimulation) in comparison
ith standard methods of outcome analysis.
ethods: By using a primary dataset containing 1847 patients and 14,429 patient-
ears, advantages and disadvantages of standard methods of outcome analysis are
iscussed, and the potential role of microsimulation is illustrated by means of a
tep-by-step explanation of building, testing, and using such a model.
esults: Total life expectancy, event-free life expectancy, and reoperation-free life
xpectancy for a 65-year-old male patient were 10.6 years, 9.2 years, and 9.8 years,
espectively. Lifetime risk of reoperation due to structural valve deterioration was
3.3%.
onclusions: Microsimulation is capable of providing accurate estimates of age-
elated life expectancy and lifetime risk of reoperation for patients who underwent
ortic valve replacement with the Carpentier–Edwards supra-annular valve. It pro-
ides a useful tool to facilitate and optimize the choice for a specific heart valve
rosthesis in a particular patient.
umerous reports have been published documenting the results of aortic
valve replacement (AVR) with different types of valve prostheses. In most
reports, emphasis is on the performance of the various prosthetic valves, as
easured by the occurrence rates of valve-related complications and their conse-
uences, and time-to-event analyses. This is a valid approach, but it is limited by
everal methodologic issues,1 and it is often not easy to translate these outcomes into
he actual consequences for the patient who requires AVR.
We have previously developed an alternative method to study outcome after
VR that allows direct estimation of patient outcome after AVR: microsimulation.2
his method solves most of the methodologic limitations of standard outcomes
nalyses but does have several limitations of its own.
The goal of this article is to provide insight into microsimulation methodology
nd to give an overview of the advantages and disadvantages of microsimulation
vascular Surgery ● September 2007
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CDompared with standard methods of outcome analysis. This
ill be done by using primary data on outcome after AVR
ith the Carpentier–Edwards supra-annular valve (CE-
AV) prosthesis from a large single center in Canada.3 The
ollowing issues will be addressed:
1. Using the primary dataset on outcome after AVR
with the CE-SAV prosthesis, we will discuss the
advantages and disadvantages of standard methods of
outcome analysis.
2. The information from this primary dataset will then
be used to estimate patient outcome with a micro-
simulation model, illustrating step-by-step the con-
struction and testing of a microsimulation model and
its potential advantages and disadvantages.
aterials and Methods
escription Dataset
or this study, a primary dataset containing 1847 AVR procedures
ith the CE-SAV device was used to estimate the parameters of
he Weibull distributions.3 These operations were conducted from
ebruary 1982 through December 1999 at the affiliated teaching
ospitals of the University of British Columbia in Canada, namely
t Paul’s Hospital, Vancouver General Hospital, and the Royal
olumbian Hospital.
The characteristics of the complete dataset (n  1847) are
ummarized in Table 1. To calculate the input of the microsimu-
ation model, 85 aortic valve rereplacements were excluded, re-
ulting in 1762 remaining primary AVRs (see Table 1 for charac-
eristics). Details of the occurrence of valve-related events and the
ssociated mortality of these primary AVRs are given in Table 2.
alve-related events were defined according to the Society of
horacic Surgeons/American Association for Thoracic Surgery
uidelines for Reporting Morbidity and Mortality after Cardiac
alvular Operations,4 with 2 modifications: transient ischemic
ttacks were not counted as neurologic events (to avoid recall
ias), and structural valve deterioration (SVD) was only included
f diagnosed either at reoperation or autopsy.
Slight differences in reporting numbers of valve-related events
etween this article and the earlier report of essentially the same
ataset3 can be explained by the use in the present study of a subset
f 1762 patients and by differences in definition of SVD.
tandard Methods of Outcome Analysis
he Kaplan–Meier (KM) and actuarial methods are commonly
Abbreviations and Acronyms
AVR  aortic valve replacement
CE–SAV Carpentier–Edwards supra-annular valve
EFLE  event-free life expectancy
KM  Kaplan–Meier
LE  life expectancy
SVD  structural valve deteriorationsed time-to-event models to estimate the survival of patients after c
The Journal of ThoracicVR. The distribution of the time to death for currently alive
atients is assumed to follow the pattern of those who have already
ied. These methods have now been extended to summarize valve-
elated events, such as SVD, that are not necessarily fatal. In
igure 1 the cumulative (actuarial) risk of reoperation for SVD
alculated by using the KM method (the complement of cumula-
ive freedom from reoperation for SVD) is displayed for the
E-SAV dataset. For estimating the lifetime risk of nonfatal
vents, the KM and actuarial methods assume noninformative
ensoring: they assume that the risk of dying and the risk of SVD
re independent, which in fact is not true (patients with high risk
f death have lower risk of SVD, and patients with low risk of
eath have a higher risk of having SVD at some time in their lives).
he KM and actuarial methods therefore estimate the freedom
rom SVD by also censoring patients who have not yet experi-
nced the event, including those who have died and will therefore
ever have the event. In doing so, they describe the risk of SVD for
he patient based on the assumption of immortality, resulting in a
igher probability of SVD than that actually had by the patient.
his effect is magnified with advancing age of valve implantation
nd could serve to underestimate the benefits of biologic valve
mplantation. Therefore although the KM and actuarial methods
re perfectly capable of analyzing fatal events, for describing
ompeting events, their value is dubious because in clinical med-
cine the assumption of noninformative censoring can often not be
uaranteed.
One of the alternate methods of summarizing complications
hat are not necessarily fatal, such as SVD, is the cumulative
ncidence or “actual” analysis.5,6 This method takes into consid-
ration the competing risk of death, it excludes future events
ttributed to already deceased patients, and it therefore calculates
he percentage of patients who will experience an event before
hey die, answering the more pertinent question of the lifetime risk
f the event.1,7-9 As is shown in Figure 1, the cumulative actuarial
isk of reoperation for SVD (7.0% at 15 years) is higher than the
ctual patient risk of reoperation for SVD (4.3% at 15 years).
The guidelines for reporting morbidity and mortality after
ABLE 1. Dataset summary
Total dataset
Only primary AVR
included
o. of procedures 1847 1762
ollow-up
Total follow-up (patient-years) 14,429 13,849
Mean follow-up time (y) 7.8 7.9
Range (y) 0–20.6 0–20.6
ale (%) 69.1 68.7
ean age (y) 69.0 69.4
perative mortality 5.3 5.0
utcome
Valve-related morbidity* 311 292
Valve-related mortality 158 154
Valve-related reoperations 161 148
Valve-related events 469 446
VR, Aortic valve replacement. *Valve-related morbidity is defined as a
onfatal valve-related event, thus including nonfatal reoperations.ardiac valve operations have also incorporated the actual meth-
and Cardiovascular Surgery ● Volume 134, Number 3 703
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CDd.4 Except for the cumulative incidence estimation, competing
isk analyses in general do have the disadvantage of assuming that
he competing events are independent. However, occurrence of an
vent (or reintervention) might alter the subsequent survival time
nd alter the risk of reoccurrence of the event.
An advantage of the KM method and the cumulative incidence
ethod is that they can be performed with standard statistical
oftware and that they give a valid general impression of outcome
n patient populations after valve replacement. However, there are
everal limitations to these methods. In both KM and cumulative
ncidence analysis, an event can only occur once in the same
atient. After the occurrence of an event, the patient is excluded
rom the analysis. Furthermore, although the KM and cumulative
ncidence analyses permit any hazard function, whereas the para-
etric exponential method requires a constant hazard, neither of
hese models take into account that event risk might change over
ime and might change after occurrence of events.
ABLE 2. Occurrence rates of valve-related events and th
VR procedures with the CE-SAV bioprosthesis
vent Occurrence
Linearized
occurrence
rate
No
reope
emorrhage 72 0.52
onstructural dysfunction 33 0.24 2
rosthetic valve endocarditis 46 0.33 1
tructural valve deterioration* 118 Weibull 9
hromboembolism 155 1.12
alve thrombosis 4 0.03
VR, Aortic valve replacement; CE-SAV, Carpentier–Edwards supra-annula
Six patients died at reoperation for structural valve deterioration, and 20 p
onfirmed at autopsy.
Figure 1. Cumulative incidence of reoperation and
reoperation”) of all-cause reoperation and reopera
patients in the Carpentier–Edwards supra-annular valve
04 The Journal of Thoracic and Cardiovascular Surgery ● Septeimulation Methods
o obtain optimal insight into outcome after valve replacement in
particular population, ideally all patients should be followed over
ime until everybody has died, and all events (not only the first)
hat took place over time should be analyzed. In real life, the
ormer is usually not a realistic option and the latter is difficult and
ime-consuming to achieve by using standard methods of outcome
nalysis. Simulation methods offer a complementary tool to stan-
ard methods of outcome analysis by simulating the lives of virtual
atients until death and taking into account all complications that
ight occur over time (including repeating events and changing
azards over time, with the occurrence of prior events, or both).
The two types of simulation models that have been used to
odel patient outcomes after AVR are the Markov state-transition
odel and the microsimulation model.2,10 The Markov model
reates a virtual population of patients that is followed over dif-
sociated reoperation and mortality rates for 1762 primary
s
Proportion
undergoing
reoperation (%)
No. of
fatalities
Proportion
fatalities (%)
Proportion fatalities
if not undergoing
reoperation (%)
0 23 31.9 31.9
87.9 3 9.1 50.0
37.0 19 41.3 62.1
83.1 26† 22.0 100.0
0 65 41.9 41.9
100.0 0 0 Not applicable
. *Structural valve deterioration was confirmed at reoperation or autopsy.
ts did not undergo reoperation but died with structural valve deterioration
ulative risk (equivalent of “1 minus freedom from
caused by structural valve deterioration (SVD) fore as
. of
ration
0
9
7
8
0
4
r valve
atiencum
tion(CE-SAV) dataset.
mber 2007
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CDerent time intervals until all patients have died. At each time
nterval, a transition from one health state to the other can occur,
epending on predefined operative mortality estimates, occurrence
ates of valve-related events and their consequences (death or
eoperation), and the probability of dying of other non–valve
elated causes. Events can occur repeatedly over time, and hazards
an change with each time interval, but it is hard to change hazards
fter the occurrence of an event by using a Markov model.
A microsimulation model is a computer model that simulates a
epresentative population but at the level of the individual: the
icro level. The remaining life (until death) of a single patient
ith a particular age and sex after AVR with a given valve type is
imulated. It takes into account the morbidity and mortality that the
atient might experience according to predefined estimates of
perative mortality, event occurrence and their consequences
death or reoperation), and the probability of dying of other non–
alve related causes. By repeating this simulation multiple times
eg, 10,000 times), a virtual patient population is generated, con-
isting of identical patients with all possible outcomes after AVR.
detailed account of the microsimulation structure and method-
logy has been given previously.2,11
We used the AVR microsimulation model, designed at our
nstitution, to provide insight into the age- and sex-related life
xpectancy (LE) and lifetime risks of valve-related events after
VR with the CE-SAV bioprosthesis because it has several ad-
antages over the Markov model. First, the microsimulation model
llows simulation of the individual life histories of patients, start-
ng directly after AVR and ending with the death of the patient
follow-up does not end at the event), rather than following a
irtual population over time. By simulating multiple times, the
ives of identical virtual patients, all possible competing events that
ight occur during the remainder of life, and the time to occur-
ence of these events can be studied. Then, by using this virtual
losed-cohort dataset, the average prognosis (including the lifetime
isk of SVD and of other valve-related events) of an individual
atient with these characteristics can be calculated. Furthermore,
nlike the Markov model, in which time is divided in intervals
uring which an event might or might not occur, the microsimu-
ation model estimates the time to the next event based on the
ccurrence probability of that event. Finally, the microsimulation
odel allows for adjustment of event occurrence rates with time or
ased on the occurrence of prior events (eg, operative mortality
ncreases with age and with each successive reoperation).
uilding a Microsimulation Model
igure 2 shows the general structure of the microsimulation model,
ncluding and itemizing the information that is needed to start
uilding the model.
Operative mortality estimates. To obtain accurate (and age-
elated) estimations of operative mortality after AVR, these pa-
ameters were estimated by using data derived from an earlier
eta-analysis containing 5837 patients with a total follow-up of
1,874 patient-years.11 Operative mortality was estimated as 2.6%
or a 40-year-old man, increasing with an odds ratio of 1.034 for
ge (per year). For a 69-year-old man, operative mortality would
e 6.6%. The real operative mortality derived from the CE-SAV
ataset for primary AVR (mean age 69 years) was 5.0%. 3
The Journal of ThoracicEstimates of occurrence rates of valve-related events. The
stimates of occurrence rates of valve-related events are derived
rom the primary dataset described earlier (patients with primary
VR only) and are depicted in Table 2. Assuming a constant
azard over time, weighted mean estimates of linearized annual
ccurrence rates were calculated for valve thrombosis, thrombo-
mbolism, endocarditis, and nonstructural dysfunction, respec-
ively. The occurrence of hemorrhage was modeled as an age-
ependent hazard of 0.076, with an age-dependent mortality of
.034.12
A reoperation because of SVD is more relevant to the patient
han the occurrence of SVD without consequences.7 Furthermore,
he onset and severity of SVD is difficult to measure. Hence SVD
as defined as “reoperation caused by SVD” or “SVD confirmed
y means of autopsy.” The cumulative risk of SVD in a biopros-
hesis decreases with increasing age of the patient at valve implan-
ation and increases subexponentially with elapsing time since
mplantation.13 Grunkemeier and colleagues14 have shown that the
eibull distribution, a generalization of the exponential distribu-
ion, was efficient in summarizing SVD in biologic valves.15
owever, they stressed that at least 12 years of follow-up are
eeded to provide reliable estimates.14 We used primary data on
he CE-SAV bioprosthesis, with a 20-year follow-up, as de-
cribed in the previous section, to calculate the parameters of the
eibull distributions.3 The value of the scale () parameter of the
eibull model, fitted to represent SVD depends on age:  
2.22400.0154*Age
. The shape parameter () was estimated at
igure 2. General structure of the microsimulation model. AVR,
ortic valve replacement..316. With the resulting age-dependent Weibull distributions for
and Cardiovascular Surgery ● Volume 134, Number 3 705
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A
CDeoperation caused by SVD, median time to reoperation caused by
VD in the supra-annular valves was 19.2 (range 18.0–20.5), 22.4
range 20.5–24.6), and 26.2 years (range 23.1–29.7), respectively
or 55-, 65-, and 75-year-old male patients.
Mortality risk associated with each valve-related event. The
stimates of mortality risk associated with each valve-related event
re derived from the primary dataset described earlier and are
epicted in Table 2.
Reoperation risk associated with each valve-related event.
he estimates of reoperation risk associated with each valve-
elated event are derived from the primary dataset described earlier
nd are depicted in Table 2.
Mortality risk associated with each reoperation. The esti-
ates of reoperative mortality risk were also obtained from the
revious meta-analysis discussed above.11 For each first and fol-
owing reoperation in a single patient, the operative mortality of
.5% was increased, with an odds ratio of 1.7. The mean age of the
atients undergoing reoperation in the CE–SAV dataset was 53
ears, and therefore the expected reoperative mortality in the
ataset would be as follows: 2.7%  1.034(53-40)  1.7  5.9%.
gain, this reoperative mortality was comparable with the ob-
erved reoperative mortality in the CE–SAV dataset, which was
.4%.
Estimate of mortality risk caused by other factors (mortality
isk of general population plus excess mortality). The mortality
f a patient after valve replacement is composed of the mortality of
he general population, the operative mortality, the valve-related
ortality, and an excess mortality. This excess mortality cannot be
xplained by valve-related events but is due to mortality associated
ith underlying valve pathology, left ventricular function, in-
reased occurrence of sudden unexpected unexplained death, and
he underreporting of valve-related events, respectively.16-18 The
odel calculates patient outcomes by superimposing the morbidity
nd mortality estimates of valve-related events on the other com-
onents of patient mortality.
The mortality of the general population was incorporated into
he model by means of the life table of the relevant age- and
ex-matched population, American male subjects in this analy-
is.19 The excess mortality, not accounted for by the valve-related
vents, was represented by age- and sex-specific hazard ratios.
hese hazard ratios have previously been estimated by approxi-
ating age- and sex-specific survival curves produced by the
odel, which contained background morbidity and mortality
aused by valve-related events to the corresponding empiric curves
btained from data on stented porcine bioprostheses that contained
ll 3 components of patient mortality.20,21 The hazard ratios were
.9, 1.8, 1.2, and 0.8 for male patients aged 45, 55, 65, and 75
ears, respectively.16 The LE of a 65-year-old patient, for exam-
le, was estimated at 10.6 years. This corresponds to a 10-year
urvival of 50%, which is comparable with survival in other
eports.22-24 However, it is in contrast to an LE of 13.8 years for
65-year-old male patient in the relevant general population,
hich translates to a 78% relative LE for the patient. The relative
E of a 65-year-old hypothetical patient who is immune from
alve-related events and from operative mortality was about 90%.
n the latter instance, the excess mortality of the patient might be
elated to underlying valve pathology, left ventricular residual
ypertrophy, and functional abnormality. f
06 The Journal of Thoracic and Cardiovascular Surgery ● SepteKvidal and colleagues,17 who investigated this excess mortality
fter heart valve replacement, described an increasing excess haz-
rd during follow-up and a decreasing excess hazard with advanc-
ng age of implantation. This supports a “multiplicative” excess
ortality, which was a structural assumption in our model. The use
f an “additive” model might overestimate LE estimates, espe-
ially in patients younger than 70 years.
esults
unning a Microsimulation Model
y repeatedly simulating individual life histories of male pa-
ients aged 55, 65, and 75 years a total of 10,000 times, the
icrosimulation model calculated actuarial patient survival,
eoperation-free survival, and event-free survival of male pa-
ients of different ages at valve implantation. The areas under
he respective curves represent LE, reoperation-free LE, and
vent-free life expectancy (EFLE). LE, reoperation-free LE,
nd EFLE for men at different ages of valve implantation are
iven in Figure 3.
The microsimulation model also calculated the actual or
ifetime risks of valve-related events and SVD after valve
mplantation. The risk of SVD reduced with advancing age
f implantation, namely 31.8%, 13.3%, and 3.6%, respec-
ively, for 55-, 65-, and 75-year-old male subjects. The
ifetime risk of having at least 1 event also decreased with
ncreasing implantation age.
esting a Microsimulation Model
Validation. There are 2 types of validation: internal and
xternal validation. Internal validation tests whether the
esults of the microsimulation model correspond to the
utcome in the dataset from which the model was derived.
or example, observed survival in the CE-SAV dataset was
7% at 15 years, whereas this was 21% by using the
icrosimulation model for a 69-year-old patient (mean age
f the CE-SAV population). Furthermore, observed actual
igure 3. Life expectancy (LE), event-free life expectancy (EFLE),
nd reoperation-free life expectancy (RFLE) for men at different
ges of valve implantation.reedom from all-cause reoperation in the dataset was 86%
mber 2007
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CDt 15 years, whereas this was 82% for a 69-year-old patient
y using microsimulation.
External validation tests whether a model also performs
atisfactorily for patients other than the ones from whose
ata the model was derived. Figure E1 displays the age- and
ex-specific survival results of the model with correspond-
ng survival curves for the Carpentier–Edwards standard
ioprosthesis (Edwards Lifesciences LLC, Irvine, Calif).
his dataset was obtained from the Providence Health
ystem in Portland, Oregon.25 The survival outputs of the
icrosimulation model for 55- and 65-year-old male
atients compared favorably with the corresponding
urves of the Carpentier–Edwards standard Portland ex-
erience through 25 years after implantation: the 10-
ear-survival of a 55- and 65-year-old male patient was,
espectively, 64% and 50% in the model versus 65% and
3% in the Portland dataset. However, the model showed
slight overestimation of mortality for 75-year-old male
ubjects compared with the Portland dataset: the 10-year-
urvival was 32% in the model versus 40% in the Port-
and dataset. Patients who undergo an operation in this
ge group do not strictly represent the average patient in
his age group who actually requires AVR. In fact, they
epresent a selection of relatively healthier patients with
relatively better LE. Systematic variations in the patient
rofile, too, especially in the older age groups, might
esult in these differences between model output and
omparison data.
Sensitivity analysis. The effect of uncertainty in the
arameter estimates of the model, such as variability across
ubgroups, can be investigated by means of sensitivity anal-
sis. In one-way sensitivity analysis the value of one prob-
bility is varied, whereas others are kept constant to test the
tability of the analysis’ conclusions and to test whether the
utcome might change, depending on the characteristics of
he subgroup.26 It ignores interactions between different
arameters and can therefore underestimate the level of
ABLE 3. Summary of sensitivity analysis for a 65-year-old
arameter
Baseline
estimate
Plausible range*
Favorable Unfavorable
emorrhage 0.52 0.39 0.65
onstructural dysfunction 0.24 0.18 0.30
rosthetic valve endocarditis 0.33 0.25 0.42
tructural valve deterioration† 22.4 28.0 16.8
hromboembolism 1.12 0.84 1.40
alve thrombosis 0.03 0.02 0.04
xcess mortality (hazard ratio) 1.2 0.9 1.5
VR, Aortic valve replacement; CE-SAV, Carpentier–Edwards supra-annu
stimate the plausible range. †Median time to reoperation caused by struncertainty. Multivariate sensitivity analysis would be pre- S
The Journal of Thoracicerred, but then also the distributions of the parameters have
o be known, which in our study is not yet possible. For this
eason, we performed one-way sensitivity analysis, and
ariation of the estimates by their 95% confidence intervals
ielded only very small changes in the long-term outcomes.
herefore we defined larger ranges by increasing and de-
reasing the baseline estimates by 25%. The resulting LE
nd EFLE of a 65-year-old male patient for a plausible
ange of valve-related events and additional mortality is
iven in Table 3. It shows that variation in the hazard ratio
epresenting excess mortality had the most pronounced ef-
ect on both LE and EFLE, and it underscores the impor-
ance of the excess mortality on the outcomes of patients
fter AVR.
iscussion
icrosimulation has several important limitations. First,
icrosimulation is a simplification of reality, just like any
ther model. Adding more variables will result in more
atient-specific outcome estimates and will bring the model
loser to reality. We intend to study the effect of parameters
uch as left ventricular function, cardiac rhythm, and renal
unction. However, it is very difficult to derive the neces-
ary data from published studies: more high-quality primary
atasets are needed for this refinement of the microsimula-
ion model. In addition, currently, the microsimulation
odel uses point estimates of the occurrence rates of valve-
elated events, ignoring the variation in these estimates. We
re currently developing a new extension of the microsimu-
ation model that allows entering not only point estimates of
he occurrence rates of valve-related events but also the
istribution of these estimates. Furthermore, in the model
e assume (by definition) all patients with SVD either have
reoperation or die, whereas in reality a proportion of
atients with SVD, particularly the elderly, will not receive
reoperation and will die of other causes. Therefore, the
odel will slightly overestimate the risk of reoperation for
le patient after AVR with the CE-SAV
fe expectancy (y)
Event-free life
expectancy (y)
Reoperation-free life
expectancy (y)
rable Unfavorable Favorable Unfavorable Favorable Unfavorable
.7 10.4 9.3 9.1 9.9 9.8
.6 10.6 9.3 9.2 9.9 9.8
.6 10.5 9.3 9.2 9.9 9.8
.8 10.6 9.7 8.7 10.3 9.2
.7 10.5 9.4 9.1 9.9 9.7
.6 10.6 9.2 9.2 9.8 9.8
.0 9.5 10.2 8.4 10.9 9.0
lve. *The baseline estimates were increased and decreased by 25% to
l valve deterioration.ma
Li
Favo
10
10
10
10
10
10
12
lar vaVD, especially in the higher age group.
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A
CDSecond, the current simulation model is based on certain
tructural assumptions regarding mortality and morbidity
fter AVR. For example, a constant hazard was assumed for
he valve-related events other than SVD. Certain hazards of
omplications, such as hazard of bleeding, will not be
onstant over time but will increase with advancing age or
ave a high-risk and a lower-risk phase, such as endocar-
itis. Therefore, in our model there is an age-dependent risk
nd age-dependent mortality for “bleeding.” The model
oes not have a 2-period risk for endocarditis because we do
ot have access yet to primary datasets to support these
hanging hazards over time. Furthermore, sudden unex-
ected unexplained death is incorporated in the excess mor-
ality because gaining insight into this determinant remains
ifficult.27
The third limitation is the fact that the quality of the
odel, as in any model, is directly dependent on the quality
f the input. Especially for input in simulation models,
igh-quality data are essential. Most of the model input is
btained from meta-analysis of earlier published studies,
argely with a retrospective design, which are generally
nown to underestimate the incidence of (valve-related)
vents. Furthermore, heterogeneity between the studies and
ossible publication bias can diminish the quality of the
odel input.
Finally, another disadvantage is the fact that the micro-
imulation software is not yet available in standard statisti-
al software packages. However, the computer program,
long with an extensive manual to get started with micro-
imulation, is available at www.cardiothoracicresearch.nl.
onclusions
his study aimed to provide insight into microsimulation
ethodology and to give an overview of the advantages and
isadvantages of simulation methods (in particular micro-
imulation) in comparison with standard methods of out-
ome analysis. It showed, using a large existing dataset,3
hat microsimulation is capable of translating valve perfor-
ance into patient outcome by providing age-related LE
nd risk of reoperation for patients who underwent AVR
ith the CE-SAV bioprosthesis. These estimates of patient
utcome might be used to compare the patient lifetime risk
f reoperation with the CE-SAV bioprosthesis with the
ericardial valves and with newer bioprostheses in a com-
arable patient population.
This study also showed that microsimulation has several
isadvantages and limitations that need to be considered
arefully and dealt with systematically when attempting to
erform simulation studies.
In conclusion, microsimulation can be a quick, accurate,
nd useful tool to assess patient outcome after AVR with a
pecific prosthetic heart valve. Outcomes after implantation
f different prosthetic heart valves can easily be compared
08 The Journal of Thoracic and Cardiovascular Surgery ● Septeo facilitate and optimize the choice of specific heart valve
rostheses for both physician and patient.
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